Medical Marijuana and the Invisible Wounds of Ukraine’s War
By Matthew Parish
Tuesday 6 October 2026
War produces injuries that can be photographed and injuries that cannot. A shattered apartment block can be recorded, measured and reconstructed. A soldier who has lost a leg can be fitted with a prosthesis. A civilian wounded by flying glass can be treated by a surgeon. Yet some of the most persistent injuries produced by Russia’s invasion of Ukraine exist within the mind: nightmares, hypervigilance, panic, insomnia, depression, survivor’s guilt and the peculiar inability to return psychologically from a battlefield even after one has returned physically. Ukraine will be treating these wounds for decades.
The scale of the problem is already formidable. The World Health Organization reported in 2026 that 72 per cent of Ukrainians surveyed had experienced anxiety or depression during the preceding year, while only one in five had sought professional assistance. These figures should not be confused with a diagnosis of post-traumatic stress disorder (PTSD), which is a specific psychiatric condition requiring clinical assessment, but they nevertheless reveal the extraordinary psychological burden that four years of full-scale war have imposed upon Ukrainian society. WHO has also documented immense pressure upon the country’s healthcare system, including thousands of attacks upon healthcare facilities, workers, ambulances and medical warehouses since February 2022.
Against this background, Ukraine’s experiment with medical cannabis deserves serious consideration. This is no longer an entirely theoretical debate. Ukraine created a legal framework for cannabis-based medicines and, in June 2026, the State Expert Centre of the Ministry of Health announced that the first Ukrainian patients had received medical cannabis medicines through electronic prescriptions. Significantly, some of the first recipients were war veterans. Ukraine has therefore crossed the important conceptual frontier between discussing cannabis medicine and actually incorporating cannabinoid-based preparations into regulated medical practice.
There is an obvious humanitarian argument for doing so. Soldiers suffering from persistent nightmares, chronic pain and sleeplessness do not care very much about the cultural history of cannabis prohibition. They want to sleep. They want to stop waking at three o’clock in the morning believing that an explosion they heard two years earlier has happened again. They want to sit in a café without instinctively calculating the nearest exit. They want, in short, to live ordinary lives again. If a medicine can safely assist them in doing this, then the fact that the active ingredient was once associated principally with an illicit recreational drug is not in itself a persuasive reason for refusing it.
Nevertheless, the medical case is considerably more complicated than the humanitarian instinct might suggest. Cannabis is sometimes discussed as though its effectiveness against PTSD were already scientifically established. It is not. A substantial 2026 review examined 26 studies involving 3,598 patients, including seven randomised controlled trials. Only one of those trials demonstrated a clear statistically significant clinical advantage over placebo, involving the synthetic cannabinoid nabilone and PTSD-related nightmares. Trials involving inhaled or oral cannabis generally failed to demonstrate superiority over placebo. Observational studies have reported improvements in nightmares, hyperarousal, sleep and quality of life, but these studies suffer from substantial methodological limitations.
That distinction is important because wartime desperation can encourage medical enthusiasm to run ahead of medical science. Another systematic review published in 2024 found a similarly mixed picture: some studies suggested improvements in particular PTSD symptoms, while others found no benefit or even worsening symptoms. Patients who also suffered from cannabis-use disorder appeared particularly vulnerable to adverse outcomes. The argument for medical cannabis in Ukraine therefore cannot responsibly be that cannabis has been proved to cure PTSD. It has not.
The more persuasive argument is narrower. Ukraine faces an exceptional population of traumatised soldiers and civilians whose symptoms are heterogeneous and whose responses to conventional treatment will likewise differ. Medicine frequently proceeds not by discovering one miraculous treatment but by assembling a collection of imperfect tools and identifying which combination works for a particular patient. Psychotherapy, trauma-focused treatment, antidepressants, treatment for anxiety, sleep interventions, physical rehabilitation, social support and family counselling may all have roles. There is no obvious reason why carefully prescribed cannabinoid medicines should be excluded from that therapeutic toolbox merely because their evidence base remains incomplete.
Indeed, the emphasis should be upon the word medical. There is an enormous difference between a traumatised veteran buying an unknown substance from an illicit dealer and a psychiatrist prescribing a standardised cannabinoid preparation whose THC and CBD concentrations are known, whose dosage is controlled and whose effects are monitored. The first is self-medication conducted outside the healthcare system; the second is medicine accompanied by clinical supervision. Ukraine should be interested in moving vulnerable people from the former towards the latter rather than pretending that traumatised people will refrain from self-medication simply because the state would prefer them to do so.
This distinction also explains why medical cannabis should not become shorthand for unrestricted cannabis consumption. THC can produce anxiety, cognitive impairment and other psychiatric effects in some people, while frequent cannabis use can develop into cannabis-use disorder. A major recent clinical review notes that US veterans’ treatment guidelines recommend against cannabis or cannabinoids as a treatment for PTSD because the evidence remains weak and psychiatric adverse effects are known.
Ukraine should pay attention to such caution without necessarily treating another country’s clinical guidelines as the final answer to the peculiar medical circumstances created by Europe’s largest war since 1945.
There is also a question of military readiness. An active soldier carrying a rifle, driving a vehicle, operating artillery or working with explosives cannot simply be treated in the same manner as a civilian patient sitting safely at home. Psychoactive medicines of many kinds can impair judgement and reaction times. The armed forces therefore require rules distinguishing treatment of veterans from treatment of active personnel and, within the latter category, distinguishing soldiers temporarily removed from operational duties from those performing safety-critical tasks. Medical compassion and military discipline are not contradictory principles; a competent regulatory regime must accommodate both.
Ukraine nevertheless possesses an unusual opportunity. Because the country unfortunately has such a large population exposed to extreme trauma, it could become an important centre for rigorous research into the treatment of war-related PTSD. Carefully designed clinical trials could examine different cannabinoid formulations, dosages and ratios of THC to CBD, distinguishing effects upon nightmares, insomnia, anxiety, intrusive memories, chronic pain and overall PTSD severity. They could also investigate whether cannabinoids are useful primarily for particular symptoms rather than for PTSD as a whole. Existing research suggests precisely why such trials are needed: promising signals exist, particularly concerning sleep and nightmares, but the evidence is nowhere near strong enough to justify extravagant claims.
Such research should be integrated with psychotherapy rather than imagined as its replacement. There is something particularly dangerous about the idea that trauma can simply be chemically extinguished. PTSD involves memories, associations, behaviours and patterns of fear that often require sustained psychological treatment. Research involving patients with both PTSD and substance-use disorders has continued to find benefits from trauma-focused therapy, including among people who use cannabis. A bottle of cannabinoid medicine should therefore never become an inexpensive substitute for the psychiatrists, psychologists and therapists whom Ukraine urgently needs.
This points towards the larger problem. Ukraine’s mental-health crisis cannot be resolved primarily through pharmacology, whether the medicine in question is cannabis, antidepressants or sleeping tablets. WHO’s finding that only a minority of people experiencing substantial psychological distress seek professional assistance suggests a problem involving availability, affordability, stigma and the sheer capacity of the healthcare system. Medical cannabis might help some patients, but it cannot repair marriages damaged by war, reintegrate veterans into employment, rebuild destroyed communities or provide companionship to somebody who has lost almost everyone they knew.
Yet neither should moral prejudice prevent physicians from exploring a potentially useful medicine. The history of pharmacology is full of substances that are dangerous when abused and valuable when properly prescribed. Opioids can create devastating dependency, yet nobody seriously proposes that morphine should therefore disappear from battlefield medicine. Benzodiazepines can be abused, as can sleeping medication and many other drugs. The appropriate question is not whether cannabis can be misused. Plainly it can. The question is whether particular cannabinoid medicines, administered to particular patients in controlled doses under medical supervision, can produce benefits greater than their risks.
Ukraine’s emerging system should therefore be conservative without being timid. Prescriptions should involve proper diagnosis and follow-up. Products should have standardised composition and quality control. Patients with histories suggesting elevated risks of psychosis, problematic substance use or other relevant contraindications require particular care. Doctors need training that is based upon evidence rather than either enthusiasm or prejudice, while prescribing patterns and adverse outcomes should be systematically recorded. Most importantly, patients should be told what medical science actually knows: there are indications of benefit for some symptoms and some individuals, but cannabis is not an established cure for PTSD and the quality of evidence remains limited.
There is something fitting about Ukraine becoming a place where this question is approached pragmatically. Wartime Ukraine has little luxury for abstract cultural battles about whether cannabis is inherently virtuous or inherently wicked. Her hospitals contain people in pain. Her cities contain civilians who have heard too many explosions. Her armed forces contain men and women who have experienced events that most Europeans cannot easily imagine. Some will recover quickly. Others will carry the battlefield inside them for years.
The case for medical marijuana in wartime Ukraine ultimately rests not upon fashionable enthusiasm for cannabis but upon medical pluralism. When millions of people have been exposed to extraordinary psychological trauma, physicians should have access to every treatment that has a plausible therapeutic rationale, provided that its uncertainties are acknowledged and its risks controlled. Medical cannabis may eventually prove highly useful for certain PTSD symptoms, modestly useful for others and ineffective or harmful for some patients. At present, science does not permit us to say much more confidently than that.
But uncertainty is an argument for research and careful medicine, not prohibition by instinct. Ukraine has already taken the first steps towards a regulated medical-cannabis system. The sensible course now is to make that system scientific, cautious and humane: prescribe where clinically justified, monitor what happens, conduct serious Ukrainian research and resist both the evangelists who imagine cannabis to be a universal cure and the prohibitionists who imagine that a medicine becomes immoral because the same plant can be used recreationally.
After this war, Ukraine will have an immense reconstruction project. Some of the ruins will be made of concrete and steel, and those will be comparatively straightforward to rebuild. The reconstruction of human beings will be harder. If cannabinoid medicines can make even a modest contribution to that work — helping some veterans sleep, reducing certain nightmares or allowing particular patients to engage more successfully with therapy — then they deserve a place in the conversation. Ukraine owes her traumatised soldiers and civilians neither miracles nor moral lectures. She owes them the widest range of treatments that careful science can responsibly provide.
